G-protein-coupled receptors (GPCRs) are fundamentally involved in mammalian physiology, whereas GPCR dysfunction/dysregulation is a major contributor to the pathophysiologies of disease. Reactive oxygen species (ROS), including superoxide (O 2 À ) and H 2 O 2 as well as reactive nitrogen species (RNS), including nitric oxide and its biological metabolites S-nitrosothiols (SNOs) are generated following GPCR activation in vascular cells. The major source of ROS is a NADPH oxidase in the vasculature, and nitric oxide is generated by nitric oxide synthase (NOS). This review will summarize the recent information on how ROS and SNOs regulate GPCR signaling and trafficking, which is implicated in vascular biology and pathophysiologies.
activate guanosine monophosphate (cGMP)-dependent signaling pathways but also directly modify the SH residues of proteins through S-nitrosylation, which has emerged as an important posttranslational modification regulating nitric oxide-mediated signaling. Under physiological conditions, nitric oxide might provide protection to cells from oxidative stress by S-nitrosylation of some critical protein thiols, preventing them from further oxidative modification by ROS. Increased oxidative stress and the formation of peroxynitrite (OONO À ) via reaction of nitric oxide with O 2 À , which can irreversibly damage cells by oxidation of free thiols and nitration of tyrosine residues, are implicated in the pathogenesis of cardiovascular diseases.
Role of reactive oxygen species in G protein-coupled receptor angiotensin II type 1 receptor signaling Angiotensin II (Ang II) is a pleuripotential hormone in vascular smooth muscle cells (VSMCs) and is a potent mediator of vascular hypertrophy, a hallmark of vascular wall remodeling and hypertension. These effects are mediated, in large part, through the GPCR AT 1 receptors (AT 1 Rs). Many growth-related outputs of the AT 1 R are dependent upon the production of NAPDH oxidasederived ROS [5] . The proto-type phagocyte NADPH oxidase consists of membrane-bound gp91 phox (now also termed Nox2) and p22 phox , which comprise the flavocytochrome b 558 , together with the cytosolic p47 phox , p67 phox p40 phox , and the small guanosine triphosphatase (GTPase) Rac. Nonphagocytic NADPH oxidase (Nox) consists of several homologues of Nox2, including Nox1, Nox3, Nox4, and Nox5, as well as the Dual oxidases (Duox) [6] [7] [8] [9] . In VSMCs, Nox1 and Nox4 are mainly responsible for ROS generation [10] . Targets of NADPH oxidase-derived ROS include protein tyrosine kinases, protein tyrosine phosphatases (PTPs), protein kinase C, mitogen-activated protein (MAP) kinases, Ca 2þ channels, and transcription factors, including nuclear factor-kB (NF-kB), activator protein-1, and Nrf2 [11, 12] .
Activation of AT 1 R induces ROS-dependent transactivation of epidermal growth factor receptor (EGFR) [13] , which serves as a scaffold for the assembly of signaling complexes, including cSrc and downstream adaptors Shc/GRB2 [14] . Transactivation of EGF receptor is necessary for activation of extracellular-signal-regulated kinase1/2 (ERK1/2) and Akt, which are involved in vascular hypertrophy [14] . How ROS mediate Ang II-induced EGFR transactivation? Lipid rafts are cholesterol-rich and sphingolipid-rich, plasma membrane domains, and 'caveolae' constitute a distinct subset of lipid rafts with cell surface flask-shaped invaginations that contain caveolin-1 (Cav1) [15] . Caveolae/lipid rafts concentrate multiple signaling molecules, including GPCRs, receptor tyrosine kinases such as EGF receptor, Src family kinases, and G proteins to form signaling platforms, which are necessary for rapid and efficient activation of downstream signaling pathways [16] [17] [18] . Thus, these specialized plasma membrane microdomains play an important role in activation of specific ROS-dependent redox signaling events [19] [20] [21] . In VSMCs, NADPH oxidase Nox1 is found in Cav1containing membranes under unstimulated conditions [22] , and Ang II stimulation promotes AT 1 R binding to Cav1 as well as trafficking of AT 1 R from high-density noncaveolar membrane fractions into caveolae/lipid rafts [23] . This in turn promotes Rac1 translocation into caveolae/lipid rafts to increase localized ROS production [24] , which is required for transactivation of EGF receptor [13] . Tyrosine phosphorylated EGF receptor and Cav1 through ROS-dependent cSrc activation subsequently appear at focal adhesions where NADPH oxidase Nox4 and paxillin localize, thereby forming redox signaling platforms. Either inhibition of NADPH oxidase or Cav1 knockdown blocks Ang II-induced increase in vascular hypertrophy [23, 25, 26] . These findings indicate that caveolae/lipid rafts are signaling domains in which AT 1 R couples with NADPH oxidase to increase ROS locally, thereby forming active redox signaling platforms involved in EGFR transactivation and vascular hypertrophy [21] (Fig. 1 ).
Figure 1 Caveolae-dependent angiotensin II type 1 receptormediated redox signaling in vascular smooth muscle cells
Angiotensin II (Ang II) stimulation promotes angiotensin II type 1 (AT 1 ) receptor trafficking into caveolin-1-enriched membrane fractions where Nox1 is found. This causes localized reactive oxygen species (ROS) production and ROS-cSrc-dependent transactivation of the epidermal growth factor receptor (EGFR) and its egress from caveolae. Tyrosine phosphorylated EGFR and caveolin-1 subsequently appear at focal adhesions where Nox4 and paxillin localize, thereby forming redox signaling platforms. These events are essential for activation of specific redox signaling pathways such as Akt involved in vascular hypertrophy. Note that Src homology 2 (SH2) domain-containing tyrosine phosphatase (SHP-2) is target of Nox1-derived ROS, which is involved in Akt activation, thereby contributing to AT 1 R-mediated hypertension. VSMC, vascular smooth muscle cell.
Protein tyrosine phosphorylation is controlled by the tightly regulated balance between protein tyrosine kinases and PTPs [27] . The reversible oxidative inhibition of PTPs by ROS is an important mechanism through which ROS increase tyrosine phosphorylation signaling events [27] [28] [29] [30] . PTP activity is dependent on reactive cysteine (Cys-SH) with a low pK a at their active site that are readily susceptible to reversible oxidation by H 2 O 2 [31] . Tabet et al. [32 ] recently demonstrated that Ang II inactivates Src homology 2 (SH2) domain-containing tyrosine phosphatase (SHP-2) PTPs through Nox1derived ROS-mediated oxidation and phosphorylation. In spontaneously hypertensive rats (SHRs), Ang IIstimulated SHP-2 oxidation/inactivation is enhanced, whereas its phosphorylation is blunted. These SHP-2 actions are associated with augmented Akt signaling, indicating the importance of Nox1-SHP2-Akt axis for Ang II-mediated hypertension in SHRs (Fig. 1) . Given that several PTPs, including SHP-2, are localized in caveolae/lipid rafts [33] , localization of AT 1 R, NADPH oxidase, and its targets signaling molecules or kinases in caveolae may play an important role in specific activation of ROS-mediated GPCR signaling. Whether this ROSdependent organized mechanism can apply to other GPCR signal transduction remains unknown.
Role of S-nitrosylation in G protein-coupled receptor signaling
Accumulating evidence indicates that GPCRs signaling is also regulated by S-nitrosylation of Cys residues at active or allosteric sites of proteins via nitric oxide and SNOs [34, 35] . The activation of neuronal N-methyl-D-aspartate (NMDA) receptors produces nitric oxide, which S-nitrosylates both the receptor itself and associated regulatory and effector proteins that play roles in NMDA receptor trafficking and signaling [34, [36] [37] [38] [39] . Cys residues that are S-nitrosylated by nitric oxide have been identified in the b 2 -AR [40] and AT 1 R [41] . Other nitric oxide-mediated S-nitrosylated proteins include Akt, caspases, cyclooxygenase-2, endothelial NOS (eNOS), Hsp90, estrogen receptor, hypoxia-inducible factor-1, NF-kB [42] , adenylate cyclase [43] , and calcium channel [44] .
Functionally, SNOs treatment prevents tachyphylaxis to b 2 -AR agonist-induced vasodilatation [45] or airway relaxation [45, 46] . Mice with a genetic alteration that impairs breakdown of SNOs are protected from tachyphylaxis [46] . Conversely, b 2 -AR tachyphylaxis is induced in vivo by the inhibition of NOS [45] , which depletes endogenous SNOs [47, 48] . Kokkola et al. [35] reported that SNOs such as S-nitrosoglutathione (GSNO) and S-nitrosocysteine (CysNO) potentiate M2/M4 muscarinic responses by increasing guanine nucleotide exchange as well as number of high-affinity [ 35 S]GTP-gS binding sites for the agonist-activated receptor. In con-trast, SNOs inhibit P2Y 12 receptor signaling in rat brain and human platelets without affecting human P2Y 12 receptor signaling under heterologous expression in Chinese hamster ovary (CHO) cells. This indicates that the cellular signaling partners, rather than the P2Y 12 receptor protein itself, are molecular targets of SNOs. Furthermore, Nozik-Grayck et al. [49] reported that SNOs inhibit GPCRs 5-hydroxytryptamine-adrenergic or a-1-adrenergic receptor agonist-stimulated pulmonary vasoconstriction via cGMP-independent mechanism involving S-nitrosylation of the receptor or a related protein. Given that the endogenous NOS is located in close proximity with the GPCR signaling complex, which is modulated by exogenous SNOs, these findings suggest that GPCR signaling in vivo is likely to be subject to receptor-specific modulation by nitric oxide and SNOs.
S-Nitrosylation of G protein-coupled receptor kinase 2, dynamin, and b-arrestin in G protein-coupled receptor b-adrenergic receptor signaling
Transduction through GPCRs is regulated by agonistinduced desensitization, in which receptors are functionally uncoupled from G protein activation, and by internalization, in which receptors undergo endocytosis followed by recycling or degradation [1,2]. The GPCR kinases (GRKs) phosphorylate agonist-occupied GPCRs and promote their desensitization and internalization [3, 50] . Receptor phosphorylation promotes the recruitment of the scaffolding protein b-arrestins to the activated receptor, where they prevent further activation of heterotrimeric G proteins, thereby desensitizing the receptor while promoting clathrin-mediated receptor endocytosis [1-3]. Nitric oxide directly regulates desensitization and internalization of GPCR by modulating the function of GPCR trafficking machinery through S-nitrosylation [34, 35, 40, 41, 51, 52] . Activation of the b-AR results in dynamic S-nitrosylation of both dynamin [52, 53] and GRK2 [54] , which serve as critical components of GPCR trafficking.
Wang et al. [52] reported that the GTPase dynamin, which regulates endocytic vesicle budding from the plasma membrane and interacts with NOS, is S-nitrosylated at a single Cys607 after stimulation of the b 2 -AR. S-Nitrosylation increases dynamin self-assembly and GTPase activity and facilitates its redistribution to the membrane. In nitric oxide-generating cells, expression of mutant dynamin C607A inhibits b 2 -AR internalization, whereas nitric oxide enhances internalization of b 2 -AR. Thus, nitric oxide regulates endocytic vesicle budding by S-nitrosylation of dynamin. Whalen et al. [54] reported how nitric oxide and/or SNOs prevent the loss of b-AR signaling in vivo. In mice, SNOs increase b-AR expression and prevent agonist-stimulated receptor downregulation; and in cells, SNOs decrease GRK2-mediated b-AR phosphorylation and subsequent recruitment of b-arrestin to the receptor, resulting in inhibiting receptor desensitization and internalization. GRK2 S-nitrosylation of Cys340 increases following stimulation of multiple GPCRs with agonists (Fig. 2) . These findings suggest novel mechanism through which GPCR signaling is regulated by nitric oxide and SNOs. Ozawa et al. [55 ] recently reported that isoproterenol stimulates the S-nitrosylation of b-arrestin 2 by eNOSderived SNOs. In human umbilical vein endothelial cells, S-nitrosylation of b-arrestin 2 promotes its dissociation from eNOS and its association with clathrin heavy chain/ b-adaptin, thereby facilitating internalization of the b 2 -AR into the clathrin-based endocytotic pathway, which in turn denitrosylates b-arrestin 2. S-nitrosylation seems to play an important role in regulating the b-arrestin-dependent trafficking of GPCRs, including the AT 1 R that are functionally coupled to eNOS [56] . S-nitrosylation is the only known facilitatory modification of b-arrestins, because phosphorylation of b-arrestin 1 or 2 inhibits clathrin-mediated b 2 -AR internalization [57] [58] [59] . Selective S-nitrosylation of b-arrestin 2 versus b-arrestin 1 provides for differential regulation of these widely distributed isoforms. Of note, stimulus-induced dephosphorylation of Ser412 in b-arrestin 1 is prerequisite for clathrin binding and receptor endocytosis [57, 58] . In contrast, b-arrestin 2 does not contain an equivalent C-terminal Ser residue, but has a highly conserved Cys410. The dephosphorylation of Ser412 of b-arrestin 1 promotes clathrin binding, and this effect is recapitulated by S-nitrosylation of Cys410 within b-arrestin 2. Thus, S-nitrosylation of b-arrestin may cooperate with phosphorylation and is important mechanism by which nitric oxide influences GPCR function via regulating protein-protein interaction of b-arrestin 2 [52, 54] (Fig. 2) .
b-Arrestin-regulated b-AR trafficking is directed primarily through clathrin-based rather than caveolar-based pathways [1,2]. However, eNOS colocalizes with b-AR primarily in caveolae through association with the scaffolding protein Cav1. As eNOS associates with both dynamin and b-arrestin, and indirectly with GRK2 through Akt [52, 54, 60] , S-nitrosylation of these three receptor trafficking elements appears to be mediated by discrete pools of eNOS. Thus, coordinated changes in the S-nitrosylation of multiple, functionally interrelated receptor trafficking machinery subserve dynamic regulation by nitric oxide [34] . Whether S-nitrosylation/ denitrosylation may influence the class characteristics of GPCRs by altering their affinity for b-arrestin 2, or whether S-nitrosylation differentially regulates signaling dependent upon b-arrestin isotypes [61, 62] are subjects of future investigation.
Role of reactive oxygen species and S-nitrosylation in G protein-coupled receptor signaling in vascular pathophysiologies
In VSMCs, production of ROS and the consequent activation of ROS-mediated GPCR signaling are involved in cell growth, migration, collagen deposition, and altered matrix metallopeptidase (MMP) activity [12] .
In endothelial cells, nitric oxide/SNO-mediated S-nitrosylation of GPCR machinery plays an important role in normal GPCR trafficking and signaling. Nitric oxide might provide protection to cells from oxidative stress by S-nitrosylation of some critical protein thiols, preventing them from further oxidative modification by ROS. Oxidative stress stimulates activation of transcription factors NF-kB and activator protein-1 and pro-inflammatory genes, chemokine production and recruitment of inflammatory cells (monocytes and macrophages), which are involved in vascular inflammation and injury [63] . Further, excess amount of ROS impairs endotheliumdependent relaxation, increases GPCR-mediated contractility, and alters vascular tone. These effects may be regulated indirectly by reducing nitric oxide bioavailability by reaction of O 2 À and nitric oxide to produce ONOO À . Thus, excess ROS production and loss of S-nitrosylation will be a potential factor in vascular dysfunction that involves altered GPCR trafficking and signaling linked to hypertension, atherosclerosis, heart failure, and diabetes.
Conclusion
NADPH oxidase-derived ROS and NOS-derived SNOs are now recognized as important second messengers to regulate GPCR signaling, thereby contributing to various physiological and pathophysiological functions. SNOs and protein S-nitrosylation may serve multiple roles to mitigate oxidation of proteins induced by NADPH oxidase-derived ROS produced following GPCR activation. Dysregulation of GPCR signaling and trafficking due to oxidative stress may contribute to various pathophysiologies in hypertension, atherosclerosis, heart failure, and diabetes. Thus, further understanding of the molecular mechanisms of ROS-dependent and nitric oxide-dependent GPCR signaling should provide new therapeutic targets for intervention in cardiovascular diseases.
